Evidence map›Paper›PMID 37548869›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2024

Status of head and neck brachytherapy in Spain in 2022.

Jose Luis Guinot, Patricia Diezhandino, Jesus Maria de Frutos, Naiara Fuentemilla, Victor Gonzalez-Perez, Cristina Gutierrez, Antonio Herreros, Rafael Martinez-Monge, Susana Perez-Echagüen, Francisco Pino and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Jose Luis GuinotRadiation Oncology Department, Fundacion Instituto Valenciano de Oncologia (I.V.O.), C/Profesor Beltran Baguena 8, 46009, Valencia, Spain. jguinot@fivo.org.ORCID http://orcid.org/0000-0001-7659-7032
Patricia DiezhandinoRadiation Oncology Department, Hospital Clinico Universitario de Valladolid, Valladolid, Spain.
Jesus Maria de FrutosRadiation Oncology Department, Hospital Clinico Universitario de Valladolid, Valladolid, Spain.
Naiara FuentemillaRadiation Oncology Department, Hospital Universitario de Navarra, Pamplona, Spain.
Victor Gonzalez-PerezDepartment of Medical Physics, Fundacion Instituto Valenciano de Oncologia (I.V.O.), Valencia, Spain.
Cristina GutierrezDepartment of Radiation Oncology, Institut Català d'Oncologia, Barcelona, Spain.
Antonio HerrerosRadiation Oncology Department, Hospital Clínic Universitari, Barcelona, Spain.
Rafael Martinez-MongeDepartment of Oncology, Clínica Universitaria de Navarra, CUN, Pamplona, Spain.
Susana Perez-EchagüenRadiation Oncology Department, CIBIR - Complejo Hospitalario San Pedro La Rioja, Logroño, Spain.
Francisco PinoDepartment of Medical Physics, Institut Català d'Oncologia, Barcelona, Spain.
Susana RoldánRadiation Oncology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Angels RovirosaRadiation Oncology Department, Hospital Clínic Universitari, Barcelona, Spain.
Miguel Angel SantosRadiation Oncology Department, Fundacion Instituto Valenciano de Oncologia (I.V.O.), C/Profesor Beltran Baguena 8, 46009, Valencia, Spain.
Camilo Jose Sanz-FreireMedical Physics Department, CIBIR - Complejo Hospitalario San Pedro La Rioja, Logroño, Spain.
Elena VillafrancaRadiation Oncology Department, Hospital Universitario de Navarra, Pamplona, Spain.
Fundación Instituto Valenciano de Oncología · ESHospital Clínico Universitario de Valladolid · ESHospital San Pedro · ESHospital Universitari de Vic · ESInstitut Català d'Oncologia · ESClinica Universidad de Navarra · ESHospital Universitari i Politècnic La Fe · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBrachytherapy (BT) has been used for many years for disease control in tumours of the head and neck area (H&N). It is currently performed with high dose rate (HDR) or pulsed dose rate (PDR), but its use has been reduced due to the implementation of new non-invasive external beam radiotherapy techniques such as intensity modulation (IMRT) and volumetric modulated arc therapy (VMAT) and the improvement of surgical techniques.

methodsThe Spanish Brachytherapy Group (GEB) has carried out a survey to find out the number of centres in Spain that continue to use BT in H&N and its indications and expectations for the future.

resultsThe results were presented at the XX GEB Consensus Meeting held on October 21, 2022, in Valencia (Spain) and it was confirmed that, although there are fewer and fewer centres that use BT in H&N, there are still units with extensive experience in this technique that should be positioned as referral centres.

conclusionIt is necessary to carry out continuous work with other specialities involved, such as H&N surgeons, and other radiation oncologists, to improve the training of residents, both oncologists and medical physicists.

Indexed as

BrachytherapyRadiotherapy, Intensity-ModulatedHumansNeckRadiotherapy DosageRadiotherapy Planning, Computer-AssistedSpainBrachytherapyCarcinomasHead and neckHigh dose rate

Identifiers

PMID37548869
OpenAlexW4385621030

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.